The National Health Fund (NFZ) spent PLN 4.00bn (€939m) on drug reimbursement in the first four months of 2018, according to official figures. This marks an increase of 5% compared with the corresponding period of 2017. The amount represents 32% of the NFZ’s estimated reimbursement spend in 2018 as a whole, which is now projected at PLN 12.4bn (€2.9bn).
Of the total amount spent in January-April 2018, NFZ expenditure on the reimbursement of Rx products available in the pharmacy channel – medicines, foods for particular nutritional uses, and medical devices – totalled PLN 2.9bn (€668m) and was 4% higher than in the first four months of 2017. The figure represents 34% of the annual plan, which is PLN 8.4bn (€2.0bn).
Reimbursement of hospital drugs via drug programmes reached PLN 953m (€223m), up 6% year on year. The amount represents 29% of the full-year plan, which is PLN 3.3bn (€771m).
Reimbursement of chemotherapy drugs totalled just under PLN 204m (€48m) in January-April 2018, up 7% y-o-y. The amount represents 30% of the annual plan (PLN 687m or €160m).
|NFZ spending on drug reimbursement (PLN m), change (%, y-o-y) and its share (%) in planned annual budget (PLN m), January-April 2018|
|* including PLN 8m reserve|
|PMR based on NFZ, 2018|
|Specification||Jan-Apr 2017||Jan-Apr 2018||Change||Planned budget for 2018||Spending in Jan-Apr 2018 as a percentage of planned budget|
|Medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel||2,737.6||2,856.9||4.4%||8,382.7||34.1%|
|Reimbursement via drug programmes||896.8||952.6||6.2%||3,302.6||28.8%|